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Abstract
Objective To determine the preventive effect of manual lymph drainage
on the development of lymphoedema related to breast cancer.
Design Randomised single blinded controlled trial.
Setting University Hospitals Leuven, Leuven, Belgium.
Participants 160 consecutive patients with breast cancer and unilateral
axillary lymph node dissection. The randomisation was stratified for body
mass index (BMI) and axillary irradiation and treatment allocation was
concealed. Randomisation was done independently from recruitment
and treatment. Baseline characteristics were comparable between the
groups.
Intervention For six months the intervention group (n=79) performed a
treatment programme consisting of guidelines about the prevention of
lymphoedema, exercise therapy, and manual lymph drainage. The control
group (n=81) performed the same programme without manual lymph
drainage.
Main outcome measures Cumulative incidence of arm lymphoedema
and time to develop arm lymphoedema, defined as an increase in arm
volume of 200 mL or more in the value before surgery.
Results Four patients in the intervention group and two in the control
group were lost to follow-up. At 12 months after surgery, the cumulative
incidence rate for arm lymphoedema was comparable between the
intervention group (24%) and control group (19%) (odds ratio 1.3, 95%
confidence interval 0.6 to 2.9; P=0.45). The time to develop arm
lymphoedema was comparable between the two group during the first
year after surgery (hazard ratio 1.3, 0.6 to 2.5; P=0.49). The sample size
calculation was based on a presumed odds ratio of 0.3, which is not
included in the 95% confidence interval. This odds ratio was calculated
as (presumed cumulative incidence of lymphoedema in intervention
group/presumed cumulative incidence of no lymphoedema in intervention
group)×(presumed cumulative incidence of no lymphoedema in control
group/presumed cumulative incidence of lymphoedema in control group)
or (10/90)×(70/30).
Conclusion Manual lymph drainage in addition to guidelines and
exercise therapy after axillary lymph node dissection for breast cancer
is unlikely to have a medium to large effect in reducing the incidence of
arm lymphoedema in the short term.
Trial registration Netherlands Trial Register No NTR 1055.
Introduction
Worldwide,breastcanceristhemostcommoncancerinwomen.
Detection and treatment of breast cancer have significantly
improved over past decades, which results in higher survival
rates.
1 More attention is now therefore paid to complications
related to treatment, such as arm lymphoedema.
For a woman with breast cancer, lymphoedema is a debilitating
and incurable problem that is caused by reduced transport
capacity of the lymph system (related to the surgery or
radiotherapy, or both), sometimes combined with an increase
in lymph load (related to hypertension, for example).
2 3 Twelve
months after axillary lymph node dissection, the point
prevalence of arm lymphoedema ranges from 12%
4 to 26%,
5
though some have reported point prevalence rates up to 70%.
6
This wide variety is related to differences in treatment of breast
cancer, methods of measurement, delay in measuring, and
definition of lymphoedema.
7 Use of the most accurate and
reliable method for assessment is crucial to advance our
understanding of preventive strategies.
8 To register the natural
differencebetweenthedominantandnon-dominantarm,volume
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RESEARCHand circumferences of both arms have to be assessed before
axillary lymph node dissection.
9 Commonly used definitions
for arm lymphoedema, taking into account preoperative
differences, are a change of 200 mL or more in volume
10 or a
change in circumference of 2 cm or more at two adjacent
measurementsites,
11bothcomparedwiththepreoperativevalue,
together with a subjective feeling of swelling.
9 Around 67-80%
of patients with lymphoedema develop arm swelling within the
first year after axillary lymph node dissection.
12 13 Possible risk
factors are being overweight, radiotherapy (of the axilla or
supraclavicular region, or both), and the number and levels of
axillary lymph nodes dissected.
14-16
Prevention of lymphoedema after axillary dissection for breast
cancer is poorly investigated. Recently, one study showed that
acombinationofguidelines,exercisetherapy,andmanuallymph
drainage was more effective in preventing arm lymphoedema
than just guidelines.
11 In another study, fewer patients who
receivedguidelinesandexercisetherapyafteraxillarydissection
developed lymphoedema than patients without treatment,
although this difference was not significant.
10 As far as we are
aware, the preventive effect of manual lymph drainage on the
development of lymphoedema has not been investigated in a
randomised controlled trial.
17 Manual lymph drainage is an
integral part of lymphoedema treatment. It is a gentle massage
technique and has different purposes: stimulating resorption of
lymphbythelymphcapillaries,increasinglymphtransportfrom
the hand to axilla by existing lymph collaterals, and creating
lymph collateral pathways between the arm and trunk and
between both axillas (that is, the Mascagni pathway and
axilloaxillary anastomoses).
18 19
We compared the effect of a treatment programme consisting
of guidelines, exercise therapy, and manual lymph drainage
(intervention group) and the same programme without lymph
drainage (control group) on the development of lymphoedema
related to breast cancer.
Methods
Participants
Between October 2007 and February 2009, all patients with
operable breast cancer and scheduled for unilateral surgery at
the multidisciplinary breast centre of the University Hospitals
inLeuvenwereassessedbeforesurgery.Aftersurgery,patients
withanaxillarylymphnodedissectionwereaskedtoparticipate
in the study (n=337), and 160 (48%) agreed to participate. All
included patients gave written informed consent.
Procedure
Patientswererandomisedintotheinterventiongroup(receiving
guidelines about the prevention of lymphoedema, exercise
therapy, and manual lymph drainage) or a control group
(receiving guidelines and exercise therapy). Patients received
guidelines about the prevention of lymphoedema and exercise
therapy as soon as possible after surgery. Manual lymph
drainage (in the intervention group) or no lymph drainage
(control group) was started one week after removal of the
axillary drains, so five weeks after the surgery on average, and
was applied over 20 weeks. In our hospital, there is a standard
procedure to leave the drains in until less than 30 mL/day is
collected,andonaveragethistakesfourweeks.Randomisation
occurred after we had information about the adjuvant treatment
decided on at the multidisciplinary oncological consultation
(three weeks after surgery). Randomisation was performed
within each stratum by using permuted blocks (size=4). Strata
were body mass index (BMI; ≤25 v >25) and postoperative
axillary irradiation (yes/no) because these factors are the two
most important risk factors for development of arm
lymphoedemaafteraxillarydissection.
14 16Theallocationtothe
treatment groups was concealed. A different person from the
onedoingtherecruitmentandtreatmentsofpatientscarriedout
the randomisation. The sequence of randomisation was
determinedbythepatient’sidentificationnumber,whichshe/he
received after inclusion in the study.
Interventions
All patients received guidelines about the prevention of arm
lymphoedema
20: lift the arm in case of heaviness, avoid lifting
heavy objects and performing repetitive movements, use the
arm as normally as possible, avoid limb constriction, avoid
extremes of temperature, apply skin care, wear a sleeve during
a flight, and avoid an increase in weight. Patients received a
brochure with these guidelines and, on request, received extra
information during the exercise therapy sessions.
Theexercisetherapyconsistedofdifferenttreatmentmodalities.
Table 1⇓ gives an overview of the different modalities, their
purpose,andmethod.Eachsessionwasindividualandtookhalf
anhour.Atthestartofthetreatment,patientshadtocometwice
a week. Later, when the difference in shoulder mobility
compared with the value before surgery was less than 20°,
frequency was reduced to once a week, and then, if the patient
was able to start maintenance treatment, to once every two
weeks.
Patients in the intervention group also received standardised
manuallymphdrainage.Firstly,lymphnodesofneckandaxilla
wereemptied.Secondly,axilloaxillaryanastomosesatthebreast
and back and lymphatics at the lateral side of the shoulder
(Mascagnipathway)werestimulated.Thirdly,thearmandhand
were drained from proximal to distal. One session took half an
hour. Patients were scheduled to receive 40 sessions of manual
lymphdrainage,withanincreaseinfrequencyfromonceaweek
to three times a week, and then a decrease to once a week, to
create a gradual adaptation of the lymph system and not to end
too abruptly.
Four therapists performed all treatments, including providing
guidelines, exercise therapy, and manual lymph drainage. Two
therapists had more than 10 years’ experience in treatment of
lymphoedema and lymph drainage. One had followed courses
at the Vodder School Belgium, and the other was educated in
lymph drainage at the University of Brussels. They performed
more than 70% of the lymph drainage sessions. The other two
therapists were less experienced but underwent training in our
centre before the start of the study. At several times during the
study,trainingsessionswereorganisedtoensurestandardisation
and similarity of the manual lymph drainage.
Ifapatientineithergroupdevelopedarmlymphoedema,defined
as an increase of the arm volume of 200 mL or more, she or he
had to wear an inelastic bandage until the lymphoedema was
maximallydiminishedandthereafterhadtowearacustom-made
sleeve.
Assessments
Information about the breast surgery, axillary surgery, and
adjuvant treatment was collected from the medical file of the
patient.
All patients were measured before and 1, 3, 6, and 12 months
after axillary surgery in the department of physiotherapy.
Patientswithasubjectivefeelingofarmlymphoedemareceived
an extra measurement of the arm. Two blinded and well trained
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RESEARCHassessors (different from the therapists) performed the
measurements. Assessors were especially trained for the study
duringonemonth.Patientswereexplicitlyaskednottomention
their group allocation to the assessor.
Table 2 shows an overview of the primary and secondary
outcome parameters and the assessment method⇓.
At each measurement session (before and after surgery), we
assessed the volume and circumference of both arms and body
weight. Volume of the arm was measured by the water
displacementmethodwithavolumeteruptothereferencepoint
16cmproximaltotheolecranon.
21Wedevelopedareliableand
valid measurement device, consisting of a stainless steel bar on
which a tapeline was fixed every 4 cm, to measure arm
circumferenceattheolecranonand4,8,12,16,and20cmabove
and under the olecranon. Inter-rater reliability of the arm
measurementsperformedbyourassessorsrangedbetween0.94
and 0.99, depending on the measurement side.
22 We used two
differentdefinitionsforobjectivelymphoedema:anincreaseof
200 mL or more in the difference in the arm volume between
the affected and healthy side compared with the difference
beforesurgeryandanincreaseof2cmormoreinthedifference
in arm circumference between the affected and healthy side at
two or more adjacent measurement points compared with the
difference before surgery. Body weight was measured with an
electronic balance.
Furthermore, at each measurement session after surgery the
patient filled in a questionnaire we had developed to score the
presence of subjective arm lymphoedema. At 3, 6, and 12
months after surgery, the patient filled in the SF-36 to measure
health related quality of life.
23
Sample size and statistical analyses
We performed power calculations before the start of the study.
If 10% of the patients in the intervention group and 30% of the
patients in the control group developed arm lymphoedema
during the first year after the surgery and we applied a power
of 80% and α of 0.05, we would need a minimum of 146
patients. Taking into account the dropouts (10%), we had to
include 160 patients. Two studies have reported a cumulative
incidence rate of lymphoedema of 26% (160/631 patients with
breast cancer)
13 and 40% (125/287 patients with breast cancer)
8
12 and 18 months after the surgery, which is comparable with
our estimated rate for the control group. As no previous studies
have examined the additional effect of manual lymph drainage
onthepreventionofarmlymphoedema,wediscussedtheeffect
with experienced physical therapists, and they considered that
only10%ofthepatientsreceivingguidelines,exercisetherapy,
and manual lymph drainage would develop arm lymphoedema
during the first year after surgery.
We compared patients’ characteristics between the excluded
and included patients to analyse the representativeness of our
studygroup.Weusedtheindependentttestforcontinuousdata,
Mann-Whitney U test for ordinal data, and χ² test for nominal
data. Data were analysed according the intention to treat
principle. We used logistic regression analyses to compare the
cumulative incidence and point prevalence of objective
lymphoedemaandpointprevalenceofsubjectivelymphoedema
at 3, 6, and 12 months between the intervention and control
group.
24 Cumulative incidence is the rate of occurrence during
a specific time period, whereas point prevalence indicates the
occurrence of a disease at a particular point in time.
We used Kaplan-Meier survival analyses (with log rank test)
tocomparegroupsconcerningtimetoevent(forbothdefinitions
of arm lymphoedema).
25 At 3, 6, and 12 months, we compared
the change in the absolute difference in arm volume with the
value before surgery and quality of life between the two groups
with Mann-Whitney U test because the variables were not
normally distributed. All data were analysed with SPSS 17.0.
Results
Compared with non-participating (excluded) patients, included
patients were 2.8 years younger (P=0.04), had 1.3 higher BMI
(P=0.02), less often received axillary irradiation (8% v 16%;
P=0.03), and more often received chemotherapy (68% v 58%;
P=0.06). All other characteristics related to disease and
treatment,suchasnumberandlevelsoflymphnodesdissected,
type of breast surgery, surgery at the dominant side, tumour
size, lymph node stage, radiotherapy of the internal mammary
chain and medial supraclavicular region, trastuzumab and
endocrine treatment, were comparable between groups (data
not shown).
From 160 included patients, 79 were randomised to the
intervention group and 81 to the control group. Some 158
patients (99%) were measured at one, three, and six months
after surgery (77 in the intervention group and 81 in the control
group) and 154 patients (96%) at 12 months after surgery (75
and 79). Figure 1 shows the flow of patients and reasons for
dropping out⇓.
All characteristics of the two groups were comparable (table
3⇓). Four patients in the intervention group and two in the
control group had developed arm lymphoedema (increase of
200 mL or more) before the start of the 20 week treatment
period. Two patients in the intervention group and three in the
controlgroupdevelopeddeepvenousthrombosisinthehealthy
arm.Thetwopatientswiththrombosisintheinterventiongroup
had−2.4kgand2.9kgchangeofweightduringfollow-up.The
three patients with thrombosis in the control group gained
3.2-6.8 kg in weight.
Eleven patients of the intervention group (15%) received 23-29
manual lymph drainage sessions, 26 patients (36%) received
30-35 sessions, and 36 patients (49%) received more than 35
sessions. The main reason for absence during the therapy
sessions was illness related to chemotherapy and radiotherapy.
Otherreasonswereproblemswithtransport,holiday,andillness
from other cause.
Primary outcomes
Compared with controls, patients in the intervention group had
a comparable cumulative incidence rate for arm lymphoedema
defined as an increase of 200 mL or more 12 months after
surgery (18 (24%) in intervention group v 15 (19%) in control
group; odds ratio 1.3, 95% confidence interval 0.6 to 2.9;
P=0.45). Both groups also had a comparable cumulative
incidence for arm lymphoedema at three and six months after
surgery (table 4⇓). The adjusted odds ratio (corrected for risk
factors for lymphoedema such as BMI, radiotherapy of axilla
and radiotherapy of internal mammary chain and medial
supraclavicularregion,andnumberandlevelsofaxillarylymph
nodesdissected)wascomparablewiththeunadjustedoddsratio
(data not shown).
Figure 2 shows the Kaplan-Meier survival analyses for time to
develop arm lymphoedema⇓. Time to develop arm
lymphoedema defined as an increase of 200 mL or more was
comparable between the two groups during the first year after
surgery (hazard ratio 1.3, 0.6 to 2.5; log rank P=0.44). The
survival analyses corrected for the lymphoedema risk factors
gave comparable results.
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At 3, 6, and 12 months after surgery, the cumulative incidence
rate for arm lymphoedema and time to develop arm
lymphoedema (defined as increase of ≥2 cm at two or more
adjacent measurement points), the point prevalence of arm
lymphoedema (defined as increase of ≥200 mL or increase of
≥2 cm), and the point prevalence of subjective lymphoedema
were comparable between the two groups (table 4⇓).
At each follow-up both groups had a similar increase of arm
volume compared with the level before surgery. They also had
a comparable mental and physical health related quality of life
(table 5⇓).
Figures 3⇓ and 4⇓ show the distribution of the changes in arm
volume and the maximal increase in arm circumference at two
adjacent measurement points 12 months after surgery. In both
groups, the distributions are comparable. The same applied to
the results for mental and physical health related quality of life
(data not shown).
Discussion
A six month treatment programme consisting of guidelines,
exercise therapy, and manual lymph drainage applied after
axillarylymphnodedissectionforbreastcancerhadnomedium
to large effect on the prevention of arm lymphoedema than the
same treatment programme without manual lymph drainage.
The cumulative incidence of arm lymphoedema and time to
develop arm lymphoedema—defined as an increase of 200 mL
or more—were comparable between both groups (primary
outcomes), during, immediately after, and six months after the
treatment sessions. The secondary outcomes were also
comparable between both groups.
Comparison with other studies
Wecould notfindapreviousrandomised controlled trialon the
preventiveeffectofmanuallymphdrainageonthedevelopment
of lymphoedema related to breast cancer. We found only a
congress report, but the methods of the study were minimally
described.
26 They concluded that manual lymph drainage was
effective for the prevention of arm lymphoedema. At five years
aftersurgery,thepointprevalenceofarmlymphoedema,defined
as an increase of 2 cm or more, was considerably higher: 30%
in the group receiving manual lymph drainage and 45% in the
control group, whereas in our study at 12 months after surgery
the point prevalence was 15% and 9%, respectively.
Lacomba et al showed a preventive effect of a combination of
manuallymphdrainageandexercisetherapyonthedevelopment
of lymphoedema.
11 They included 120 patients after axillary
dissection, although power calculation was performed
retrospectivelyonthebasisofanestimatedcumulativeincidence
of 10% in the intervention group and 30% in the control group
and a power of 70%. Patients were treated over three weeks.
Within the first year after surgery, 7% of the patients in the
intervention group, who received guidelines, exercise therapy,
and manual lymph drainage, and 25% of the patients in the
control group, who received only guidelines, had developed
arm lymphoedema. All patients who developed arm
lymphoedema did so 6-12 months after surgery. In our study
we performed a comparable power calculation, but we did this
before the start of the study, and our power was higher (80%).
In patients in our intervention group, who also received
guidelines, exercise therapy, and manual lymph drainage, the
cumulativeincidenceratewasmuchhigher(24%).Inourcontrol
group, who received guidelines and exercise therapy, the
cumulative incidence rate was comparable (19%). In our study,
the patients developed their arm swelling earlier. In contrast
with Lacomba et al, only 36% of the patients with arm
lymphoedema (13/36) developed oedema 6-12 months after
surgery. We cannot explain this discrepancy. Our patients were
treated for a longer time (six months versus three weeks).
Perhaps our study population was at higher risk of developing
lymphoedema because of more extensive axillary surgery or
because of more frequent irradiation of the axilla. This
information is missing in the study of Lacomba et al.
11
Strengths and limitations
The present study had several strengths. The volume and
circumference of both arms were measured before surgery to
determine the natural difference in arm volume.
27 At each
follow-up, we compared the evolution of the difference in arm
volume between the affected and the healthy arm to correct for
patients’ weight gain. In some cases, the healthy arm can be
swollenbecauseofadeepvenousthrombosisafterimplantation
ofacentralvenouscatheterforchemotherapy.
28Theproportion
of patients undergoing chemotherapy before or after surgery,
however, was comparable in our two groups. We carried out
randomisation and stratification for BMI and axillary
radiotherapy to reduce potential bias concerning the most
importantriskfactorsforlymphoedemaatbaseline.Inaddition,
randomisation was concealed. Only six patients (4%) dropped
out after the start of the 20 week treatment period. Our study
populationreceivedanaverageof34sessionsofmanuallymph
drainage over 20 weeks, so we are confident that we examined
the preventive effect of manual lymph drainage.
Our study also had several limitations. Six patients developed
lymphoedema soon after axillary surgery and before the start
of the 20 week treatment period. Our patients were not entirely
representative of all patients with breast cancer, although
compared with non-participants, they were only about 3 years
younger,hadaBMIabout1higher,andfewerreceivedaxillary
radiotherapy;allothercharacteristicswerecomparable.Halfof
the therapists were experienced in performing manual lymph
drainageandhalfwerelessexperienced.Theirmethodoflymph
drainagewascomparableastheywereespeciallytrainedbefore
the study and standardisation and similarity of lymph drainage
of the four therapists was controlled at several times during the
study. In addition, the experienced therapists performed the
major part of the lymph drainage sessions. Our patients did not
receivetheplanned40manuallymphdrainagesessionsbecause
of illness related to chemotherapy, although up to 85% of the
patients received 30 sessions or more.
Future research
As we found no medium to large effect of manual lymph
drainage (in addition to guidelines and exercise therapy) on the
development of lymphoedema related to breast cancer, a future
study should be performed to determine whether it has a small
effect.Thepowercalculationcouldbebasedonthecombination
of the cumulative incidence rates for arm lymphoedema from
the study of Lacomba et al and our study, which leads to an
estimatedcumulativeincidenceof16%((4+18)/(59+77))inthe
intervention group and 21% ((14+15)/(57+81)) in the control
group.Weneedtocontinuetofollowupourpatientsas20-33%
of patients with breast cancer who develop arm lymphoedema
will do so more than 12 months after surgery.
Furtherresearchshouldconfirmourresults.Lymphoscintigraphy
canbeusedtocomparethelymphfunctionontheaffectedside
29
between the groups. Instead of circumference and volumetric
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ultrasonography. This can directly measure thickening of cutis
and subcutis because of lymphoedema and exclude changes in
arm volume caused by muscular atrophy and hypertrophy.
30 31
Conclusion and policy implication
Our results show that manual lymph drainage applied after
axillary lymph node dissection for breast cancer and additional
toguidelinesandexercise therapy isunlikelytohaveamedium
to large effect on the prevention of arm lymphoedema in the
shortterm.Itisimportanttoinformpatientsofthisafteraxillary
dissection.
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RESEARCHWhat is already known on this topic
There is no standard definition to determine arm lymphoedema related to breast cancer
The combination of guidelines about the prevention of arm lymphoedema, exercise therapy, and manual lymph drainage
is thought to be more effective than just guidelines
What this study adds
Manual lymph drainage in addition to guidelines about the prevention of lymphoedema and exercise therapy has no
medium to large effect on the prevention of arm lymphoedema related to breast cancer in the short term
Tables
Table 1| Overview of different treatment modalities applied during individual sessions of exercise therapy, with duration of 30 minutes a
session, and their purpose and description of method in patients after unilateral axillary lymph node dissection for breast cancer
Method Purpose Modality
Average 10 minutes per session. Angular passive mobilisation of shoulder (especially anteflexion
and abduction) combined with traction/translation to prevent articular problems and impingement
To improve passive and active shoulder
mobility
Mobilisation of shoulder
Average 10 minutes per session (together with scar tissue massage). Passive and active
stretching and transverse strain of major and minor pectoral muscle
To improve muscle flexibility and passive
and active shoulder mobility
Stretching breast
muscles
Mobilisation of scar tissue, by gripping scar tissue between thumbs and index fingers and moving
hands in opposite direction
To improve flexibility of scar tissue Scar tissue massage
Average 10 minutes per session. 10 exercise schemes built steadily and incrementally in difficulty.
Each exercise scheme consisted of exercise with proprioceptive neuromuscular facilitation (3×);
active stretching of breast muscles (3×15 s); four different exercises—for example, scheme 1:
1) lying supine and both hands on shoulder, perform anteflexion of both shoulders; 2) same, but
abduction; 3) same, but circumduction; 4) lying supine, hands crossed, elbows straight and 90°
anteflexion of shoulder, perform protraction of both shoulders. Scheme 5: 1) standing, holding
To improve muscle flexibility, endurance,
and strength and active shoulder mobility
and to stimulate lymphatic transport
Exercise schemes
stick in both hands on buttock with straight elbows, perform retroflexion of both shoulders; 2)
same, but on thighs, perform anteflexion of shoulders; 3) same and 90° anteflexion of shoulder,
perform horizontal abduction of affected shoulder; 4) standing, holding stick in both hands at
shoulder height, straighten elbows above head. At start of each exercise scheme, exercises
were performed 7×, then 10×, then 10× slow and 5× fast, and finally 10× slow and 10× fast.
Patients were asked to perform exercises from scheme twice/day at home, as taught during
treatment sessions
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RESEARCHTable 2| Overview of primary and secondary outcome parameters and assessment methods in patients after unilateral axillary lymph node
dissection for breast cancer
Measurement method Outcome parameter
Primary
Arm volume with water displacement method Cumulative incidence of arm lymphoedema, defined as ≥200 mL increase
Arm volume with water displacement method Time to develop arm lymphoedema, defined as ≥200 mL increase
Secondary
Arm circumferences with measurement device Cumulative incidence of arm lymphoedema, defined as ≥2 cm increase at two or more adjacent places
Arm circumferences with measurement device Time to develop arm lymphoedema, defined as ≥2 cm increase at two or more adjacent places
Arm volume with water displacement method Point prevalence of arm lymphoedema, defined as ≥200 mL increase
Arm circumferences with measurement device Point prevalence of arm lymphoedema, defined as ≥2 cm increase at two or more adjacent places
Author developed questionnaire Point prevalence of subjective arm lymphoedema
Arm volume with water displacement method Increase of arm volume
SF-36 Health related quality of life
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RESEARCHTable 3| Characteristics of patients according to treatments to prevent development of lymphoedema related to breast cancer. Figures are
numbers (percentage) of patients unless specified otherwise
Control (guidelines, exercise; n=81)
Intervention (guidelines, exercise, manual
drainage; n=77)
1 (1) 1 (1) Men
80 (99) 78 (99) Women
54.5 (11.1) 55.8 (12.5) Mean (SD) age (years)
26.2 (5.4) 26.6 (5.4) Mean (SD) BMI
8 (−16-64) 8 (−34-56) Median (IQR) increase in arm volume before start of allocated
treatment (mL)
34 (12) 40 (8) Mean (SD) interval between surgery and start of allocated treatment
(days)
Mean (SD) No of sessions:
28 (8) 28 (6) Exercise therapy
0 34 (7) Manual lymph drainage
18 (6) 19 (6) Mean (SD) No of lymph nodes
Type of breast surgery:
56 (69) 52 (66) Mastectomy
25 (31) 27 (34) Breast conserving
44 (54) 47 (60) Surgery on dominant side
Level of axillary surgery:
0 (0) 2 (3) I
54 (67) 43 (54) I-II
27 (33) 34 (43) I-III
Tumour size :
0 (0) 1 (1) pT0
26 (32) 21 (27) pT1
39 (48) 38 (48) pT2
12 (15) 13 (17) pT3
4 (5) 6 (8) pT4
Lymph node stage:
25 (31) 23 (29) pN0
39 (48) 36 (46) pN1
9 (11) 11 (14) pN2
8 (10) 9 (11) pN3
67 (83) 69 (87) Radiotherapy, IMC and medial supraclavicular
5 (6) 8 (10) Radiotherapy, axilla
58 (72) 50 (63) Chemotherapy
14 (17) 14 (18) Neo-adjuvant chemotherapy
7 (9) 14 (18) Trastuzumab
66 (82) 55 (70) Endocrine treatment
BMI=body mass index; IQR=interquartile range; IMC=internal mammary chain.
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RESEARCHTable 4| Comparison of cumulative incidence and point prevalence of arm lymphoedema after surgery for breast cancer at 3, 6, and 12
months for different definitions according to treatments to prevent lymphoedema
P value* Odds ratio (95% CI) Control (guidelines, exercise; n=81)
Intervention (guidelines, exercise, manual drainage;
n=77) Definition of lymphoedema
Primary outcome parameter
Cumulative incidence, ≥200 mL increase:
0.51 1.4 (0.5 to 4.4) 6 (7%) 8 (10%) At 3 months
0.93 0.9 (0.4 to 2.3) 12 (15%) 11 (14%) At 6 months
0.45 1.3 (0.6 to 2.9) 15 (19%) 18 (24%) At 12 months†
Secondary outcome parameters
Cumulative incidence, ≥2 cm increase:
0.51 1.4 (0.5 to 4.4) 6 (7%) 8 (10%) At 3 months
0.72 1.2 (0.5 to 2.8) 11 (14%) 12 (16%) At 6 months
0.35 1.4 (0.7 to 3.0) 16 (20%) 20 (27%) At 12 months†
Point prevalence, ≥200 mL increase:
0.43 1.8 (0.4 to 7.8) 3 (4%) 5 (7%) At 3 months
0.28 0.5 (0.1 to 1.7) 8 (10%) 4 (5%) At 6 months
0.71 1.2 (0.4 to 3.3) 8 (10%) 9 (12%) At 12 months†
Point prevalence, ≥2 cm increase:
0.67 1.3 (0.3 to 5.2) 4 (5%) 5 (7%) At 3 months
0.65 0.8 (0.3 to 2.3) 8 (10%) 6 (8%) At 6 months
0.27 1.8 (0.6 to 4.8) 7 (9%) 11 (15%) At 12 months†
Point prevalence, subjective:
0.21 1.8 (0.7 to 4.4) 9 (11%) 14 (18%) At 3 months
0.28 1.7 (0.6 to 4.4) 8 (10%) 12 (16%) At 6 months
0.34 1.5 (0.7 to 3.2) 14 (18%) 18 (24%) At 12 months†
*For logistic regression analysis.
†75 in intervention group, 79 in control group.
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RESEARCHTable 5| Comparison of changes in difference in arm volume between affected and healthy arm compared with difference in volume before
surgery for breast cancer and comparison of mental and physical health related quality of life (secondary outcomes) between groups at
each follow-up according to treatments to prevent lymphoedema
P value* Control (guidelines, exercise; n=81) Intervention (guidelines, exercise, manual drainage; n=77) Time after surgery
Change in difference in arm volume (mL):
0.69 18 (101) 29 (82) At 3 months
0.42 31 (114) 58 (104) At 6 months
0.97 45 (111) 34 (158) At 12 months†
Quality of life:
Mental health (maximum score 100):
0.70 69 (38) 72 (34) At 3 months
0.59 68 (33) 74 (42) At 6 months
0.74 81 (32) 79 (36) At 12 months†
Physical health (maximum score 100):
0.54 56 (38) 56 (27) At 3 months
0.81 58 (36) 63 (40) At 6 months
0.48 77 (35) 74 (37) At 12 months†
*For Mann-Whitney U test.
†75 in intervention group, 79 in control group.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d5326 doi: 10.1136/bmj.d5326 Page 10 of 12
RESEARCHFigures
Fig 1 Trial profile of patients with breast cancer undergoing axillary lymph node dissection according to allocation to
intervention (guidelines, exercise therapy, and manual lymph drainage) or control (guidelines, exercise therapy)
Fig 2 Time to develop lymphoedema after axillary lymph node dissection for breast cancer in 160 patients for two definitions
of lymphoedema: increase ≥200 mL in volume or increase ≥2 cm in circumference at two adjacent points
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RESEARCHFig 3 Change in difference in arm volume between affected and healthy side compared with preoperative difference 12
months after surgery for breast cancer. Vertical line corresponds to cut-off value for diagnosis of lymphoedema (≥200 mL
increase)
Fig 4 Maximum increase in difference in arm circumference between affected and healthy side at two or more adjacent
measurement points compared with preoperative difference 12 months after surgery for breast cancer. Vertical line
corresponds to cut-off value for diagnosis of lymphoedema (≥2 cm increase at two or more adjacent measurement points)
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